Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-079 in Generalized Myasthenia Gravis (Phase 2, Italy)
2019-003383-47Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in myasthenia gravis (MG) comparing TAK-079 with Placebo (2 arms). Primary endpoint: Safety and tolerability (TEAEs, Grade ≥3 events, SAEs, AEs leading to discontinuation). Started Sep 2020; status: completed.
02
Drugs
mezagitamab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2019-003383-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003383-47.